Gene Therapy, R&D

Solid Bio’s higher gene therapy dose for Duchenne MD runs smack into a fresh set of safety issues — shares tumble

Solid Biosciences has just ricocheted into a new setback.A few months after reporting dismal responses from a small cohort of patients receiving its gene therapy for Duchenne muscular dystrophy, the biotech had a chance to increase the dose to what it felt would be an ideal level — and immediately ran into a serious adverse event that had to be reported to the FDA.


In order to read this article, you must be an Endpoints News subscriber. (It's free to subscribe.)

← Go back

We produce two daily email newsletters designed to give you a complete picture of what's important in biopharma. It's free to subscribe and never any spam. Join 51,200+ biopharma executives who read Endpoints News every day.

Access is subject to the terms in our Privacy Policy.


The best place to read Endpoints News? In your inbox.

Comprehensive daily news report for those who discover, develop, and market drugs. Join 51,200+ biopharma pros who read Endpoints News by email every day.

Free Subscription

VP Oncology Biology
Skyhawk Therapeutics Waltham, MA
Associate Director CMC
Elektroki Boston, MA
Director Process Development
Elektroki Boston, MA
Research Scientist - Immunology
Recursion Pharmaceuticals Salt Lake City, UT

Visit Endpoints Careers ->